RedHill's Yeliva yields one partial response in MM patient in preliminary Phase Ib data

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said Yeliva opaganib (ABC294640) led to one very good partial response and two

Read the full 192 word article

User Sign In